November 4, 2021
Ryvu’s partner Menarini Group receives FDA Orphan Drug Designation for SEL24 (MEN1703) for the Treatment of Acute Myeloid Leukemia
Year
2021
Assets in this page
Download assets
- pdf file
Current Report ESPI 33/2021
Download
November 4, 2021
Ryvu’s partner Menarini Group receives FDA Orphan Drug Designation for SEL24 (MEN1703) for the Treatment of Acute Myeloid Leukemia
2021
Assets in this page
Download assets
Current Report ESPI 33/2021